CA3114271A1 - Inhibiteurs d'osteoclastes contre la douleur - Google Patents
Inhibiteurs d'osteoclastes contre la douleurInfo
- Publication number
- CA3114271A1 CA3114271A1 CA3114271A CA3114271A CA3114271A1 CA 3114271 A1 CA3114271 A1 CA 3114271A1 CA 3114271 A CA3114271 A CA 3114271A CA 3114271 A CA3114271 A CA 3114271A CA 3114271 A1 CA3114271 A1 CA 3114271A1
- Authority
- CA
- Canada
- Prior art keywords
- zoledronic acid
- pain
- compound
- acid
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Des composés pouvant être utilisés dans le traitement des douleurs au genou dun mammifère qui en a besoin et des utilisations connexes sont décrits. Le composé peut être un bisphosphonate. Des composés en exemple comprennent un acide zolédronique et un acide néridronique. Le mammifère nécessitant le traitement, qui peut être un humain, peut présenter une intensité de douleur de 5 cm ou plus au moyen de léchelle visuelle analogue de 0 à 10 cm et dune cote de 0 dune évaluation de lOARSI ou une cote 0 ou une cote 1 de Kellgren et Lawrence dun pincement de l'interligne articulaire.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3194798A CA3194798A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Applications Claiming Priority (55)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201414228241A | 2014-05-27 | 2014-05-27 | |
US14/228,241 | 2014-05-27 | ||
US14/288,713 | 2014-05-28 | ||
US14/288,716 US8835650B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,720 | 2014-05-28 | ||
US14/288,713 US8901162B1 (en) | 2014-01-30 | 2014-05-28 | Substituted imidazolium compounds for treating disease |
US14/288,716 | 2014-05-28 | ||
US14/288,720 US8865757B1 (en) | 2014-05-28 | 2014-05-28 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US201462012112P | 2014-06-13 | 2014-06-13 | |
US62/012,112 | 2014-06-13 | ||
US14/310,811 US8822436B1 (en) | 2012-05-14 | 2014-06-20 | Compositions for oral administration of zoledronic acid or related compounds for treating disease |
US14/310,811 | 2014-06-20 | ||
US14/336,642 | 2014-07-21 | ||
US14/336,642 US20140329773A1 (en) | 2012-05-14 | 2014-07-21 | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease |
US14/446,184 US9006279B1 (en) | 2014-01-30 | 2014-07-29 | Substituted imidazolium compounds for treating disease |
US14/446,184 | 2014-07-29 | ||
USPCT/US2014/050427 | 2014-08-08 | ||
PCT/US2014/050427 WO2015060924A1 (fr) | 2013-10-25 | 2014-08-08 | Compositions pour administration orale d'acide zolédronique ou de composés associés pour le traitement de maladies |
US14/457,659 | 2014-08-12 | ||
US14/457,659 US20140349974A1 (en) | 2014-08-12 | 2014-08-12 | Zoledronic acid dosage forms for the treatment of pain |
US14/481,097 | 2014-09-09 | ||
US14/481,097 US8962599B1 (en) | 2014-05-27 | 2014-09-09 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US201462053619P | 2014-09-22 | 2014-09-22 | |
US62/053,619 | 2014-09-22 | ||
US14/495,732 | 2014-09-24 | ||
US14/495,732 US9127069B1 (en) | 2014-06-11 | 2014-09-24 | Compositions comprising rank/rankl antagonists and related compounds for treating pain |
US14/530,556 | 2014-10-31 | ||
US14/530,556 US20150051175A1 (en) | 2012-05-14 | 2014-10-31 | Co-Administration of Steroids and Zoledronic Acid to Prevent and Treat Pain |
US14/536,526 US20150057250A1 (en) | 2012-05-14 | 2014-11-07 | Inhibitors of osteoclast activity for treating arthritis |
US14/536,526 | 2014-11-07 | ||
US14/538,709 | 2014-11-11 | ||
US14/538,709 US9290575B2 (en) | 2014-06-11 | 2014-11-11 | Compositions comprising RANK/RANKL antagonists and related compounds for treating pain |
US14/540,333 | 2014-11-13 | ||
US14/540,333 US9216168B1 (en) | 2014-05-27 | 2014-11-13 | Therapeutic compositions comprising imidazole and imidazolium compounds |
US14/604,524 | 2015-01-23 | ||
US14/604,524 US9211257B2 (en) | 2012-05-14 | 2015-01-23 | Osteoclast inhibitors for knee conditions |
US14/605,822 US9216153B2 (en) | 2012-05-14 | 2015-01-26 | Osteoclast inhibitors for knee conditions |
US14/605,822 | 2015-01-26 | ||
US14/607,985 | 2015-01-28 | ||
US14/607,947 | 2015-01-28 | ||
US14/607,947 US9289384B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/607,985 US9289385B2 (en) | 2012-05-14 | 2015-01-28 | Osteoclast inhibitors for knee conditions |
US14/608,855 | 2015-01-29 | ||
US14/608,855 US9079927B1 (en) | 2014-05-27 | 2015-01-29 | Substituted imidazolium compounds for treating disease |
US14/625,457 US9427403B2 (en) | 2012-05-14 | 2015-02-18 | Methods for the safe administration of imidazole or imidazolium compounds |
US14/625,457 | 2015-02-18 | ||
US201562127214P | 2015-03-02 | 2015-03-02 | |
US62/127,214 | 2015-03-02 | ||
US14/635,857 US9283239B2 (en) | 2012-05-14 | 2015-03-02 | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome |
US14/635,857 | 2015-03-02 | ||
US14/639,013 US9289441B2 (en) | 2014-08-08 | 2015-03-04 | Osteoclast inhibitors such as zoledronic acid for low back pain treatment |
US14/639,013 | 2015-03-04 | ||
US14/686,551 | 2015-04-14 | ||
US14/686,551 US9408860B2 (en) | 2012-05-14 | 2015-04-14 | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain |
CA2950443A CA2950443A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2950443A Division CA2950443A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3194798A Division CA3194798A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3114271A1 true CA3114271A1 (fr) | 2015-12-03 |
CA3114271C CA3114271C (fr) | 2023-06-06 |
Family
ID=57483086
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3194798A Pending CA3194798A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
CA3114271A Active CA3114271C (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
CA2950443A Abandoned CA2950443A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3194798A Pending CA3194798A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2950443A Abandoned CA2950443A1 (fr) | 2014-05-27 | 2015-05-27 | Inhibiteurs d'osteoclastes contre la douleur |
Country Status (3)
Country | Link |
---|---|
AU (3) | AU2017213506B2 (fr) |
CA (3) | CA3194798A1 (fr) |
MY (1) | MY185481A (fr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130303485A1 (en) * | 2012-05-14 | 2013-11-14 | Herriot Tabuteau | Compositions for Oral Administration of Zoledronic Acid or Related Compounds for Treating Disease |
-
2015
- 2015-05-27 MY MYPI2016704377A patent/MY185481A/en unknown
- 2015-05-27 CA CA3194798A patent/CA3194798A1/fr active Pending
- 2015-05-27 CA CA3114271A patent/CA3114271C/fr active Active
- 2015-05-27 CA CA2950443A patent/CA2950443A1/fr not_active Abandoned
-
2017
- 2017-08-10 AU AU2017213506A patent/AU2017213506B2/en active Active
- 2017-12-06 AU AU2017272199A patent/AU2017272199B2/en active Active
-
2019
- 2019-06-27 AU AU2019204559A patent/AU2019204559B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2017272199A1 (en) | 2017-12-21 |
AU2019204559B2 (en) | 2020-04-16 |
AU2019204559A1 (en) | 2019-07-18 |
MY185481A (en) | 2021-05-19 |
CA3194798A1 (fr) | 2015-12-03 |
AU2017272199B2 (en) | 2019-03-28 |
CA2950443A1 (fr) | 2015-12-03 |
AU2017213506B2 (en) | 2017-09-07 |
AU2017213506A1 (en) | 2017-08-31 |
CA3114271C (fr) | 2023-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9694023B2 (en) | Methods for the safe administration of imidazole or imidazolium compounds | |
US9707245B2 (en) | Neridronic acid for treating complex regional pain syndrome | |
US9895383B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9770457B2 (en) | Neridronic acid for treating bone marrow lesion | |
US9700570B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9675626B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9669040B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9795622B2 (en) | Neridronic acid for treating pain associated with a joint | |
US9662343B2 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US20170079995A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US20160331768A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating low back pain | |
US20170065622A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US20170079996A1 (en) | Osteoclast Inhibitors for Knee Conditions | |
US20170065625A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US20170056427A1 (en) | Dosage forms for oral administration of zoledronic acid or related compounds for treating disease | |
US20170071960A1 (en) | Osteoclast inhibitors for knee conditions | |
US9623036B2 (en) | Osteoclast inhibitors such as zoledronic acid for low back pain treatment | |
US20170049791A1 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome | |
US9511081B2 (en) | Osteoclast inhibitors for knee conditions | |
WO2015184003A1 (fr) | Inhibiteurs d'ostéoclastes contre la douleur | |
AU2019204559B2 (en) | Osteoclast inhibitors for pain | |
AU2015267046C1 (en) | Osteoclast inhibitors for pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |
|
EEER | Examination request |
Effective date: 20210407 |